Renaissance BioScience Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 22

Employees
  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

Renaissance BioScience General Information

Description

Developer of a yeast-based RNAi production and oral delivery technology designed for gene silencing in the gastrointestinal tract. The company's technology targets the reduction of inflammation for Crohn's disease, ulcerative colitis, and other gastrointestinal diseases and can also be used for animal health and environmentally friendly biopesticides that include yeast strains that prevent the formation of naturally occurring contaminants, enabling companies to deliver things that need to supply, sustain and strengthen humanity.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Food Products
Other Pharmaceuticals and Biotechnology
Primary Office
  • 410-2389 Health Sciences Mall
  • Vancouver, British Columbia V6T 1Z3
  • Canada
+1 (604) 000-0000

Renaissance BioScience Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Renaissance BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Mar-2022 000.00 Completed Generating Revenue
6. Grant 01-Jan-2021 000 000.00 Completed Generating Revenue
5. Grant 01-Jan-2020 00.000 000.00 Completed Generating Revenue
4. Accelerator/Incubator 01-Oct-2019 000 000.00 Completed Generating Revenue
3. Seed Round 00.00 00.00 000.00 Completed Generating Revenue
2. Grant 08-Jun-2017 $369K Completed Generating Revenue
1. Grant 01-Mar-2016 $50K Completed Startup
To view Renaissance BioScience’s complete valuation and funding history, request access »

Renaissance BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a yeast-based RNAi production and oral delivery technology designed for gene silencing in the gastrointesti
Biotechnology
Vancouver, Canada
22 As of 2022
000.00
0000000000 0 000.00

000000

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
000000000000000
Houston, TX
0 As of 0000
000.00
00000000000 000.00

000 00

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
000000000 000000000
Boulder, CO
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Renaissance BioScience Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlycosBio Venture Capital-Backed Houston, TX 0 000.00 00000000000 000.00
000 00000000000000 Venture Capital-Backed Boulder, CO 00 000.00 0000000000 0 000.00
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
0000000 0000000000 Formerly VC-backed London, United Kingdom 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 5 competitors. Get the full list »

Renaissance BioScience Patents

Renaissance BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019264879-A1 Yeast for producing and delivering rna bioactive molecules and methods and uses thereof Pending 09-May-2018 000000000
CA-3099445-A1 Yeast for producing and delivering rna bioactive molecules and methods and uses thereof Pending 09-May-2018 000000000
EP-3790955-A4 Yeast for producing and delivering rna bioactive molecules and methods and uses thereof Pending 09-May-2018 000000000
EP-3790955-A1 Yeast for producing and delivering rna bioactive molecules and methods and uses thereof Pending 09-May-2018 000000000
US-20210054379-A1 Yeast for producing and delivering rna bioactive molecules and methods and uses thereof Pending 09-May-2018 A01N63/50
To view Renaissance BioScience’s complete patent history, request access »

Renaissance BioScience Executive Team (11)

Name Title Board Seat Contact Info
John Husnik Ph.D Co-Founder, Chief Executive Officer, Board Member, CSO and President
Davona Walton Co-Chief Financial Officer
Michael Kirwan Co-Chief Financial Officer
Maurice Boucher Co-Founder & Executive Chairman
You’re viewing 4 of 11 executive team members. Get the full list »

Renaissance BioScience Board Members (7)

Name Representing Role Since
John Husnik Ph.D Renaissance BioScience Co-Founder, Chief Executive Officer, Board Member, CSO and President 000 0000
Maurice Boucher Renaissance BioScience Co-Founder & Executive Chairman 000 0000
Morris Chen Renaissance BioScience Board Member 000 0000
Peter Lutwyche Ph.D Self Board Member 000 0000
Vick Dusik Renaissance BioScience Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Renaissance BioScience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Renaissance BioScience Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Carpere Capital PE/Buyout Minority 000 0000 000000 0
Radicle Accelerator/Incubator Minority 000 0000 000000 0
National Research Council Canada Government 000 0000 000000 0
NorthView Lifesciences Venture Capital Minority 000 0000 000000 0
To view Renaissance BioScience’s complete investors history, request access »